Redcare Pharmacy stock: Berenberg raises target for Redcare Pharmacy stock to EUR 102.00
Published on 10/19/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget outlook and reporting date
- On October 7, 2026, Berenberg lifted its Redcare target from EUR 94.00 to EUR 102.00.
- Redcare Pharmacy will publish its third-quarter results on October 29, 2026.
- Redcare Pharmacy stock costs EUR 77.03 at Lang & Schwarz on October 19, 2026 at 3:16 p.m. CEST, 2.98 percent above the Xetra close of October 16, 2026.
- The company has a market capitalization of EUR 1.6 billion and a price-to-earnings ratio of minus 36.87.
Redcare Pharmacy (ISIN NL0012044747) trades at EUR 77.03 at Lang & Schwarz on October 19, 2026 at 3:16 p.m. CEST, up 2.98 percent versus the Xetra close of October 16, 2026 at EUR 74.80. On October 7, 2026, BÖRSE ONLINE reported that Berenberg raised its target from EUR 94.00 to EUR 102.00 and kept a Buy rating. That target is 32.42 percent above the Lang & Schwarz price.
Target revision sets the frame
The Berenberg revision gives investors a dated benchmark while the stock remains below its 52-week high. The target change followed Redcare Pharmacy's second increase to its full-year 2026 revenue-growth outlook, according to the same October 7 report.
The current price sits 9.85 percent below the 52-week high of EUR 85.45 and 155.07 percent above the 52-week low of EUR 30.20. The quoted bid was EUR 76.90 and the ask EUR 77.15 at 3:16 p.m. CEST on October 19, 2026.
October 29 results date
Redcare Pharmacy's investor-relations calendar lists the third-quarter interim statement for October 29, 2026. It also lists a Baader Bank investor event for November 2, 2026, giving the next reporting date a clear place in the calendar. The company operates digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands.
Valuation and peer view
Redcare Pharmacy has a market capitalization of EUR 1.6 billion and a price-to-earnings ratio of minus 36.87. Its trailing dividend yield is 0.00 percent. These figures describe the current valuation rather than a forecast.
Comparison with peers
Redcare Pharmacy (Xetra, EUR): plus 2.98 percent, P/E minus 36.87, market capitalization EUR 1.6 billion
DocMorris (SIX, CHF): plus 2.95 percent, P/E minus 10.15, market capitalization CHF 809.8 million
CVS Health (NYSE, USD): minus 0.24 percent, P/E 24.43, market capitalization USD 118.1 billion
Price remains below the yearly high
For German-market investors, the decisive levels are the EUR 74.80 Xetra close and the EUR 85.45 yearly high. The distance to Berenberg's EUR 102.00 target is larger than the distance to the yearly high, so the analyst benchmark and the October 29 reporting date provide the next dated reference points.
Redcare Pharmacy was trading at EUR 77.03 at Lang & Schwarz on October 19, 2026 at 3:16 p.m. CEST, up 2.98 percent versus the Xetra close of October 16, 2026 at EUR 74.80. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy market data
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- Ticker: RDC
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 19, 2026, 3:16 p.m. CEST): EUR 77.03
- Change versus Xetra close: plus 2.98 percent
- Xetra close (October 16, 2026): EUR 74.80
- Market capitalization: EUR 1.6 billion (as of October 19, 2026)
- 52-week range: EUR 30.20-85.45 (as of October 19, 2026)
- Sector / Industry: Healthcare / Medical - Distribution
- Next earnings date: October 29, 2026
Market context: Market report DAX.
